Post-intervention dual antiplatelet therapy for mild stroke

Trial details

Who runs it

Technische Universitaet Dresden

Trial code

EU 2026-525681-22-00

Record updated

2026. szeptember 25.

Original description

To investigate whether enhanced antiplatelet therapy for stroke prevention reduces the risk of recurrent stroke in patients with AIS who present with mild neurological deficits following IVT and/or EVT.Read full original descriptionShow less

POst-Therapy ENhanced Thrombocyte Inhibition At Low NIHSS score (POTENTIAL) – A randomized controlled multicenter trial

To investigate whether enhanced antiplatelet therapy for stroke prevention reduces the risk of recurrent stroke in patients with AIS who present with mild neurological deficits following IVT and/or EVT.

Inclusion: Patients of any sex aged ≥ 18 years; AIS treated with IVT (alteplase or Tenecteplase), and/or EVT AND with a post-interventional NIHSS ≤ 7 points (last documented value prior to randomization); Ability to receive oral or nasogastric drug administration; Written informed consent of the patient.

Exclusion: Concomitant use of medication with a clinically relevant interaction with ASA or clopidogrel without a therapeutic alternative (e.g., omeprazole, if switching to pantoprazole is not possible); Contraindication to MRI (non-MRI-compatible pacemaker, implants); Simultaneous participation in another interventional clinical trial (within the last 4 weeks before enrollment); Indication for dual antiplatelet therapy for more than 21 days; Evidence of intracerebral bleeding of any kind (except intracerebral bleeding of category HI1 according to the Heidelberg classification) on cerebral imaging 12-24 hours after IVT and/or EVT; Planned, non-postponable surgery with a foreseeable need to pause antiplatelet therapy (e.g. symptomatic extracranial carotid stenosis with stent implantation or endarterectomy) Acute malignant MCA infarction; Current Malignant Media Infarction; Known HIV infection; Hypersensitivity to ASA, clopidogrel, any of their ingredients, or to drugs with a similar chemical structure; Addiction or other conditions that do not allow to assess the nature, significance, and possible consequences of the clinical trial; History of non-traumatic intracranial bleeding; Major bleeding in the recent 5 years (including traumatic intracranial bleeding); Clinically relevant non-major bleeding in the last 3 months; Any indication for therapeutic anticoagulation at therapeutic dosage with phenprocoumon, heparin, apixaban, rivaroxaban, edoxaban, dabigatran (e.g. atrial fibrillation, mechanical heart valve, deep vein thrombosis); Contraindication to dual antiplatelet therapy (e.g. coagulation disorders with increased bleeding tendency); INR > 1.5 or platelet count < 100,000/mm³ or ALT ≥ 3 times the upper limit of normal or creatinine ≥ 2 times the upper limit of normal; Woman of childbearing potential, unless at least one of the following criteria is met: a. Postmenopausal (12 months of natural amenorrhea or 6 months of amenorrhea with serum FSH > 40 U/ml), b. Postoperative (6 weeks after bilateral oophorectomy with or without hysterectomy or bilateral salpingectomy), c. Regular and correct use of a contraceptive method with a failure rate < 1 % per year, d. Sexual abstinence, e. Vasectomy of the partner; At the time of admission to hospital: ASPECT Score < 5 or diffusion weighted imaging (DWI) lesion > 50% of MCI territory in cMRI; Life expectancy < 1 year; Indications that the patient is unlikely to comply with the study protocol; Pregnant or breastfeeding women; Patients dependent on the sponsor, principal investigator, or study team staff; Contraindication to ASA or clopidogrel according to the current summary of product characteristics.

EU CTIS 2026-525681-22-00